News

Lupin Q4 Results: Revenue, EBITDA meet expectations; North America leads growthSales in India made up for 34%, while North America accounted for 38% of the overall topline. The European Markets (EM) and other developed markets witnessed 11% sales each. The active pharmaceutical ingredient (API) made up for 5%.By Ekta Batra   May 15, 2025, 8:59:52 AM IST (Published)2 Min ReadDrugmaker Lupin Ltd.'s shares are in focus on Thursday, May 15, after the company reported its fourth quarter earnings on Wednesday after market hours.

The pharma company's revenue and earnings before interest taxes depreciation and amortisation (EBITDA) were in-line with estimates.

Revenue for the quarter increased by 12.2% from the same quarter last year to ₹5,567.1 crore. However, when compared to the December quarter, the topline was lower by 3.5%. A CNBC-TV18 poll had pegged the revenue to be at ₹5,537.7 crore.

Lupin's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) increased by 22.5% from last year to ₹996.85 crore. The EBITDA figure was lower than the CNBC-TV18 estimate of ₹1,209.16 crore.

The company's margin expanded to 21.9% in the fourth quarter from 20.1% in the previous year. However, it contracted from the previous quarter's 23.5%.

Lupin's profit of ₹794.86 crore was higher than expectations of ₹717.3 crore. It was up  121.1% to from ₹359.43 crore in the previous year. It was also 7.9% higher than the previous quarter's ₹736.59 crore.

Lupin's growth was led by the North American market, where sales stood at ₹2,261.8 crore from ₹1,900.6 crore in the previous year. It was up 6.6% sequentially from ₹2,121.3 crore.

US sales for the fourth quarter were at $245 million compared to $209 million in the previous year and $235 million in the previous quarter.

Sales in the growth market increased by 30% from the same quarter last year to ₹691.5 crore, while Indian markets grew by 7% from the previous year to ₹1,711.3 crore.

Sales in India made up for 34%, while North America accounted for 38% of the overall topline. The European Markets (EM) and other developed markets witnessed 11% sales each. The active pharmaceutical ingredient (API) made up for 5%.

Shares of Lupin ended 0.8% higher on Wednesday before the earnings announcement at ₹2,082. The stock is down 12% so far in 2025.

Also Read: Defence stocks have added ₹1.2 lakh crore to their market capitalisation in 12 trading sessionsContinue ReadingCheck out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsLupinshare market today